REDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today launched a groundbreaking initiative in honor of Prader-Willi Syndrome (PWS) Awareness Day. The campaign aims to raise awareness of PWS and celebrate individuals living with this life-threatening disease.
PWS is a rare and complex genetic disease affecting approximately one in every 15,000 births globally. Among its characteristics in infants are hypotonia (weak muscles), low muscle mass, and weak suck at birth. As the child develops, the hallmark symptom of potentially life-threatening hyperphagia (insatiable hunger) becomes evident, which can lead to early onset morbid obesity. Other characteristic features of PWS include significant behavioral problems, incomplete sexual ...